Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

European Union
Ivan Jurašinović v Council of the European Union (T-63/10)
Judgment
Law
The merits of the application for annu…
Preliminary observations
29

Ivan Jurašinović v Council of the European Union (T-63/10)

law://eu/cjeu/2010/t-63-10/para_29@2026-11-14

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

Key facts

Court: General Court · Second Chamber, sitting with five Judges
Case: T-63/10 · ECLI:EU:T:2012:516
Decided: 3 Oct 2012
Procedure: Action for annulment
Applicant: Ivan Jurašinović
Defendant: Council of the European Union
Rapporteur: J. Schwarcz
Bench: 5 judges
N.J. Forwood, F. Dehousse, M. Prek, J. Schwarcz, A. Popescu
Language: French
Official: CURIA · EUR-Lex 62010TJ0063

Topics

Access to documents

History · 1 version

3 Oct 2012Reading

Judgment of 3 Oct 2012

29However, that right is none the less subject to certain limitations based on grounds of public or private interest (Case C-266/05 P Sison v Council [2007] ECR I-1233, paragraph 62).

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Connections

Cited by 17: European Commission v Patrick Breyer (C-213/15 P); Päivi Leino-Sandberg v European Parliament (C-761/18 P)2 provisions; Intercept Pharma Ltd and Intercept Pharmaceuticals, Inc. v European Medicines Agency (T-377/18); Pagkyprios organismos ageladotrofon (POA) Dimosia Ltd v European Commission (T-74/16); Access Info Europe v European Commission (T-852/16); Access Info Europe v European Commission (T-851/16); French Republic v European Commission (T-344/15)2 provisions; Philip Morris Ltd v European Commission (T-796/14); Philip Morris Ltd v European Commission (T-18/15); Ivan Jurašinović v Council of the European Union (T-658/14); ClientEarth and The International Chemical Secretariat v European Chemicals Agency (ECHA) (T-245/11)2 provisions; Patrick Breyer v European Commission (T-188/12)2 provisions; Darius Nicolai Spirlea and Mihaela Spirlea v European Commission (T-669/11)2 provisions; MasterCard, Inc. and Others v European Commission (T-516/11); Ivan Jurašinović v Council of the European Union (C-576/12 P)3 provisions; European Dynamics Belgium SA and Others v European Medicines Agency (T-638/11); Leonard Besselink v Council of the European Union (T-331/11)
Cites 8: Treaty on European Union (consolidated 2016); Regulation (EC) No 1049/2001; Ioannis Terezakis v Commission of the European Communities (T-380/04); Yves Franchet and Daniel Byk v Commission of the European Communities (T-391/03, T-70/04); Kingdom of Sweden and Maurizio Turco v Council of the European Union (C-39/05); Kingdom of Sweden v Association de la presse internationale ASBL (API) and European Commission, Association de la presse internationale ASBL (API) v European Commission and European Commission v Association de la presse internationale ASBL (API) (C-514/07 P, C-528/07 P, C-532/07 P); Ivan Jurašinović v Council of the European Union (T-465/09); Jose Maria Sison v Council of the European Union (C-266/05 P)